Noronha and colleagues' 2020 randomized phase three open-label trial consisted of 350 patients with NSCLC + EGFR mutation treated with either gefitinib or gefitinib and carboplatin combination therapy. This evidence concerns the gene EGFR and non-small cell lung carcinoma.